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Uterine fibroids, the most common benign tumor in women of childbearing age, may cause symptoms including pelvic pain,
menorrhagia, dysmenorrhea, pressure, urinary symptoms, and infertility. Various approaches are available to treat symptomatic
uterine fibroids.Magnetic Resonance-guided FocusedUltrasound Surgery (MRgFUS) represents a recently introduced noninvasive
safe and effective technique that can be performed without general anesthesia, in an outpatient setting. We review the principles
of MRgFUS, describing patient selection criteria for the treatments performed at our center and we present a series of five selected
patients with symptomatic uterine fibroids treated with this not yet widely known technique, showing its efficacy in symptom
improvement and fibroid volume reduction.
1. Introduction
Uterine fibroids (or leiomyomas) are the most common be-
nign tumor of the genital tract in women of reproductive age.
According to recent longitudinal studies, the lifetime risk of
fibroids in awoman over the age of 45 years ismore than 60%,
with incidence higher in blacks than in whites [1].
Although they often are asymptomatic, nearly half of
women with fibroids have debilitating symptoms, such as
menorrhagia, dysmenorrhea, anemia, pelvic pressure or pain,
urinary symptoms, constipation, acute pain from degenera-
tion or torsion of a pedunculated fibroid, dyspareunia, infer-
tility, or miscarriage [2]. Table 1 shows a summary of uterine
fibroids characteristics.
Several approaches are now available for the treatment of
uterine fibroids, including pharmacologic options, such as
hormonal therapies and Gonadotropin-Releasing Hormone
(GnRH) agonists, and surgical approaches, such as hysterec-
tomy and myomectomy (see Table 2). The new treatment
modalities include the following: hysteroscopic resection for
submucous fibroids, laparoscopic and vaginal myomectomy,
uterine artery embolization (UAE), myolysis by heat, cold
coagulation, and laser, laparoscopic uterine artery occlu-
sion, temporary transvaginal uterine artery occlusion, and
Magnetic Resonance-guided Focused Ultrasound Surgery
(MRgFUS). Factors such as the importance of uterine preser-
vation for patient’s desire to become pregnant in the future,
symptoms severity, and tumor characteristics may affect the
choice of the best possible approach [2, 3].
MRgFUS is a noninvasive thermoablative technique that
combines the anatomic detail and thermal monitoring capa-
bilities of Magnetic Resonance Imaging (MRI) with the
therapeutic potential of High-Intensity Focused Ultrasound
(HI-FU). MRI offers excellent three-dimensional anatomic
resolution and real-time thermal monitoring, measuring tis-
sue temperature with an accuracy of ±2∘C [4]. HI-FU waves
can pass through the anterior abdominal wall and aim at the
targeted volume, where tissue temperature increases rapidly
up to 60∘C or higher, inducing a thermal lesion by protein
denaturation and resulting coagulative necrosis, while the
Hindawi
Case Reports in Radiology
Volume 2017, Article ID 2520989, 11 pages
https://doi.org/10.1155/2017/2520989
2 Case Reports in Radiology
Table 1: Summary table for uterine fibroids.
Etiology Unknown
Incidence >60% over the age of 45 years
Age predilection >30 years
Risk factors Age, black race, early age at menarche, familial predisposition, overweight, polycystic ovarysyndrome, diabetes, hypertension, nulliparity
Symptoms Menorrhagia, dysmenorrhea, anemia, pelvic pressure or pain, urinary symptoms, constipation,backache or leg pains, dyspareunia, infertility, or miscarriage
Treatment
Treatment is required in up to 25% of women. Treatment options include medications, such as
gonadotropin-releasing hormone (Gn-RH) agonists, hysterectomy, myomectomy, myolysis,
uterine artery embolization, MR-guided Focused Ultrasound Surgery (MRgFUS)
Prognosis
Benign tumor, excellent prognosis. In general, they begin to shrink after menopause, and they can
grow quickly during pregnancy. They may also bleed into themselves, degenerate, become cystic,
calcify, or undergo sarcomatous degeneration (<1% of cases)
Findings on MR imaging
Well-defined uterine mass with uniformly low signal intensity as compared to the myometrium
on T2-w images and iso-hypointense to the myometrium on T1-w images that enhances
homogeneously when gadolinium is administered intravenously. Degenerated fibroids show
complex appearance with high or heterogeneous signal on T2-w and postcontrast images
skin and overlying tissue layers outside the ablated area
remain unaffected [5].
Compared to other treatment options, MRgFUS repre-
sents a safe, effective, and noninvasive approach that may be
alternatively used as a fertility-preserving technique in se-
lected cases [4].
MRgFUS was approved by the European Community
(CE) in 2002 and by the US Food and Drug Administration
(FDA) in 2004.
This paper provides an overview of our initial clinical
experience with MRgFUS, including a brief description of
the treatment system, selection criteria, and procedure work-
flow, followed by the presentation of a case series of five
patients with symptomatic uterine fibroids treated with this
technique. These cases have distinctive features that offer
good points for discussion.
2. Clinical Series
Patients with symptomatic fibroids included in this report
were screened by means of a medical examination by a gen-
eral practitioner or a gynecologist and by a pelvic ultrasounds
examination andMRI in order to determine patients’ clinical
and technical suitability forMRgFUS treatment.We included
patient with a definitive diagnosis of uterine fibroid(s) as the
cause for their symptoms, uterus size less than 24 cm without
the cervix, the presence of less than 6 clinically significant
fibroids, absence of contraindications to MRI examination,
no massive abdominal scarring that cannot be avoided by
manipulations or covered by a US-blocking scar patch (made
of a polyethylene filmmixed with air bubbles), no evidence of
high grade Squamous Intraepithelial Lesion (SIL), and no
ongoing pregnancy or unstable medical conditions. All the
patients included in this report have read and signed an
informed consent which included the use of collected anon-
ymized data for scientific publications.
2.1. MRI Selection Criteria. Patients underwent a pelvic MRI
screening examination (Signa HDxt 1.5T scanner from GE
Medical Systems; Milwaukee, WI, USA) that included the
following sequences acquired with 4mm thick consecutive
slices: axial, sagittal, and coronal T2-weighted (T2-w) Fast
Recalled Fast Spin Echo (FRFSE), axial T1-weighted (T1-w)
Fast Spin Echo (FSE) with and without fat saturation, and,
after intravenous (i.v.) administration of 0.1mmol/kg of ga-
dobenate dimeglumine (MultiHance, Gd-BOPTA; Bracco
Imaging SpA, Milano, Italy), sagittal and coronal T1-w FSE
and axial T1-w FSE with fat saturation.
The purpose of the MRI screening examination was to
check the accessibility, viability, and texture of the fibroids.
MR images were also useful to obtain information on size,
location, number, signal intensity on T2-w images, and post-
contrast enhancement of uterine fibroid(s) as well as abdom-
inal scars in the intended beam path, presence of adeno-
myosis, and existence of other uterine disorders or any other
pathology outside the uterus. Fibroids suitable for MRgFUS
were selected in according with guidelines outlined by Yoon
et al. [6], Le´na´rd et al. [7], andmore recently byMindjuk et al.
[8].
We included patients with less than 6 clinically significant
submucosal, intramural, and/or subserosal fibroids greater
than 3 cm (since the smaller sonication spot with our MRg-
FUS system is 2.5 cm; see asterisks in Figure 1(a)) and smaller
than 10 cm (to avoid longer treatment time; Figure 1(b)).
Patients with pedunculated fibroids on a small and narrow
stalk (less than 50%of fibroid diameter)were excluded as they
may potentially disconnect from the uterus after the treat-
ment and require further surgical procedures to remove them
from the pelvic cavity (asterisk in Figure 1(c)). Fibroids with
a significantly calcified envelope were excluded as well as cel-
lular fibroids showing a bright signal onT2-w images (relative
to the uterus wall; see Figure 1(d)) and nonenhancing fibroids
on postcontrast T1-w images (Figure 1(e)).
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Table 2: Comparison of hysterectomy, myomectomy, uterine artery embolization (UAE), and MRgFUS.
Procedure Hysterectomy Myomectomy Uterine artery embolization(UAE) MRgFUS
Description
Surgical removal of the
uterus with or without the
cervix. There are several
different surgical
approaches: vaginal
hysterectomy (performed
through an incision in the
vagina), abdominal
hysterectomy (through a
horizontal incision on the
lower abdomen), and
laparoscopic hysterectomy
(through four tiny incisions
on the abdomen).
Surgical removal of one or
more fibroids from within
the uterus. It can be
performed through several
different ways: abdominal
myomectomy, laparoscopic
myomectomy, and
hysteroscopic myomectomy
(only for women with
submucosal fibroids).
UAE involves blocking,
with small particles
injected through a catheter,
the blood vessels that
supply the fibroids, causing
them to shrink.
High intensity focused
ultrasound waves heat and
destroy
fibroid tissue. The MRI
allows
guiding treatment and
monitoring tissue
temperature in realtime.
Return to normal
activities 7 to 56 days. 1 to 44 days. 3 to 10 days, 1 day.
Hospital days 1 to 5 days. 0 to 3 days. 0 to 1 day, Outpatient procedure; nohospital stay.
Procedure time 1.5 to 3 hours. 1 to 3 hours. 30 minutes to 1.5 hours, 1.5 to 4 hours.
Advantages
Fibroids will not recur
because the uterus is
removed. The ovaries may
be removed or spared.
Only the fibroids are
removed; reproductive
potential is spared.
Most fibroids can be
treated. Incision is small
and uterus is retained.
Hospital stay is short (1 day)
and in some cases may be
performed as an outpatient
procedure. Recurrence of
treated fibroids is very rare.
Return to normal activity
within 10 days.
Day care procedure
requiring no
hospitalization, no
incisions, no ionizing
radiation, no general
anesthesia. Severe
complications virtually
absent. Return to daily
activities from the next day
of treatment. Fertility is
preserved.
Disadvantages/risks
Reproductive potential is
lost. Side effects may
include early menopause
and a reduction in libido.
Removal of the ovaries in a
premenopausal woman can
lead to hot flashes, vaginal
dryness, and osteoporosis.
Possible surgical risks
include bleeding,
infections, adhesions,
injury to the intestines, or
bladder.
Fibroids can regrow and/or
new fibroids can develop
resulting in recurrent
symptoms and additional
procedures. The younger
the woman is and the more
the fibroids are present at
the time of myomectomy,
the more likely she is to
develop fibroids in the
future. Possible surgical
risks include bleeding,
adhesions, and infections.
Low risk of menopause and
blockage of blood supply to
ovaries. Possible surgical
risks include bleeding,
uterine infection, blood
clots, and injury of the
ovaries and to the uterus,
potentially leading to a
hysterectomy.
Not all type of fibroids can
be treated. Fibroids may
recur with time. It is a safe
procedure with minimal
risk; infrequent
complications are
abdominal pain/cramping,
back or leg pain, urinary
tract infection, vaginal
discharge, skin injury
(burns), and transient
nerve damage.
Future fertility Reproductive potential islost.
Possibility of pregnancy
after adequate healing time.
A cesarean section may be
required for delivery.
Unpredictable effect on
fertility. Fertility is preserved.
Fibroids with a significant portion (more than 50%) of
their volume deeper than 14 cm from the skin line (i.e., the
maximumpenetration achievable with theHI-FU transducer
we used) required mitigation techniques (thinner acoustic
coupling gel pad or rectum filling with ultrasound gel) to
reduce the distance between the targeted fibroid and the
transducer. Special attention has been given to the following
elements:
(i) Proximity to Sacrum. The center of the targeted
fibroid should be more than 4 cm from any bone
surface. Bone can be indirectly heated by the HI-
FU far field energy, which could potentially cause
secondary nerve heating, resulting in pain and fre-
quent interruptions of the treatment sessions that can
result in risk of nerve reversible or permanent injury.
Mitigation techniques to avoid sacrumproximitymay
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Figure 1: Illustrative pelvic MRI scans of excluded patients: (a) axial T2-w showing three small fibroids (asterisks) and many bowel loops
(white arrows) that are interposed between the skin surface and the hypothetic target; (b) sagittal T2-w of a large fibroidwhich almost occupies
the whole pelvis and is dangerously close to sacrum bone and nerves (this patient performed the screening MRI in supine feet first position
since she reported some discomfort in maintaining the prone position); (c) axial T2-w showing a small and pedunculated subserosal fibroid
(asterisk); (d) sagittal T2-w of a “bright” untreatable cellular fibroid; (e) axial T1-w with fat saturation acquired after intravenous injection of
paramagnetic contrast medium showing a nonenhancing fibroid; (f) sagittal T2-w of a patients with a bulky scar in abdominal skin (white
arrow).
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Figure 2: Screenshot from the ExAblate workstation showing the planned target of patient in case 3 after the first sonication performed. In
bottom left, the HI-FU beam representation is shown in light blue, the red line indicates the skin-gel pad interface, and critical structures are
secured by the use of specific low-energy density region (LEDR) and no-pass regions markers (bowel in pink, pubic bone in light blue). The
target volume (region of treatment, ROT) has been split into multiple subvolumes (green and yellow voxels) each of which will be ablated
by a specific sonication. Patients’ movements during treatment are monitored by reviewing fiducials (red crosshairs) placed by the treating
physician on distinct anatomic structures which can be monitored during real-time MR imaging. Real-time thermal mapping after the first
sonication is shown in the bottom right graph (maximum temperature achieved in the focal spot is 71∘C).
include HI-FU transducer or beam tilting and rectal
filling.
(ii) Accessibility of the Fibroid(s). Bowel (white arrows in
Figure 1(a)) and scars (white arrow in Figure 1(f))may
represent an obstacle to the ultrasound beam path. As
bowel may contain air or energy absorbing particles,
only patients with bowel that can be shifted away from
the beampath (by bladder or rectal filling) or by beam
angulationmay be treated. Extensive abdominal scars
may absorb the ultrasound energy and cause pain or
result in a skin burn.Therefore, patients with abdom-
inal scars that cannot be avoided using bladder filling
and/or beam angulation or that cannot be fully cov-
ered by an ultrasound (US) blocking scar patch may
not be suitable for MRgFUS.
(iii) Malignancy. Patients should not have any imaging
finding suggestive of uterine, ovarian, or cervical
malignancy on MRI screening evaluation.
2.2. Treatment: Planning and Execution. On the day of the
treatment, patients are shaved from the umbilicus to the
pubis; an i.v. line and a urinary catheter are inserted.The pro-
cedure is performed with the patient lying prone (feet toward
the MR gantry) on a dedicated MR detachable table which
houses the MRgFUS system. In our practice we used an
InSightec ExAblate 2100 (InSightec Ltd., Haifa, Israel) MRg-
FUS system connected to a GE HDxt 1.5T MR scanner (GE
Medical Systems; Milwaukee,WI, USA).The abdomen of the
patients lies in a water bath of deionized degassed water, in
contact with an acoustic coupling gel pad located above the
ultrasound transducer.
A light i.v. conscious sedation is administrated by an anes-
thesiologist to relieve anxiety, prevent movement, and mini-
mize discomfort during the procedure. Patients received 1 gr
paracetamol (15 minutes before laying on the MR table) and
0.03mg/Kg midazolam (at the beginning of the treat-
ment). Additional midazolam boluses (0.01–0.03mg/Kg)
were administered to keep the appropriate sedation level.
As a safetymeasure, a “stop sonication button” is placed in
patient’s hand and one more button is available on the work-
station that the operating physician uses during treatment.
These buttons are capable of the immediate suspension of
energy delivery anytime during the procedure.
Preprocedural MRI is essential to evaluate the correct
patient positioning and the adequate transducer-to-fibroid
alignment. To avoid extensive abdominal scars, bowel, or
ovaries, the transducer can be moved and tilted. The HI-FU
beam path can be changed by acting on electronic steering
through the dedicated software. Moreover, the physicianmay
accordingly modify the position of the uterus by bladder
and/or rectal filling (using saline and US gel, resp.).
Before starting a treatment, the skin-gel pad interface
needs to be defined in the dedicated software (red line in
Figure 2). This is followed by marking out the critical struc-
tures using specific low-energy density region (LEDR) and
no-pass region markers to curtail or prevent the beam path
to pass through sensitive organs (see Figure 2: bowel in pink;
pubic bone in light blue; sacrum in orange). For added safety,
patients’ movements during treatment are monitored by
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reviewing fiducials placed by the treating physician on dis-
tinct anatomic structures which can be monitored during
real-time MR imaging acquired in treatment (red crosshairs
in Figure 2). The target volume, referred to as the region of
treatment (ROT), is then defined with its safety margins. A
few low-energy sonications (usually up to 3 or 4) are per-
formed for final targeting calibration. Clinical treatment will
be performed with multiple therapeutic sonications until a
sufficient fibroid volumewill be covered (in Figure 2, the ROT
has been split into multiple subvolumes each of which will be
ablated by a specific sonication). Real-timeMR thermometry
will reveal any potentially dangerous heating or unwanted
exposure. Before the beginning of the treatment, patients are
explained what they may feel and if and when they will have
to stop the sonication: mild warming, transient pain, and
uterine cramping are usually reported by patients during son-
ications, while acute pain, signs of neurological involvement
of the lower limbs, and skin burning sensations require an
instantaneous interruption of the energy delivery. Patients
are also asked to relay all relevant sensations after each
sonication and they are constantly monitored and assessed to
check for unusual symptoms.
In our practice, the average treatment time (from the first
low-energy sonication to the last therapeutic one) was about
150 minutes.
After the treatment, postcontrast T1-w images are ac-
quired to assess the area of treated tissue (calculated as the
nonenhancing area in terms of nonperfused volume, NPV)
and to exclude any procedure-related complications.
Even if procedure-related complications aremostlyminor
and attributable to the effects from focused ultrasound along
the whole beam trajectory (near field, targeted site, and far
field), the operating physicianmust be steadily vigilant during
the treatment. The most common near field side effect is the
risk of skin burns due to bad skin-to-gel pad coupling (scars
or skin folds must be carefully avoided and/or settled) or to
targeting a site too close to the skin surface. An accurate
preparation of the patient (that include proper skin shaving
and cleansing and the use of scar patches) usually helps
preventing thermal injuries in the near field. In some patients,
abdominal wall subcutaneous and muscular edema may
occur, but this usually gradually resolves spontaneously [9]. A
proper planning and real-time MR imaging prevent target
exposures of adjacent organs. Injuries may be also avoided by
filling or emptying the bladder via a catheter and/or filling
the rectum via a rectal tube for displacing structures such
as bowel loops or ovaries out of the HI-FU beam path or to
displace the area of treatment with respect to a skin scar; in
some cases, the use of bowel mitigation techniques has been
also described to treat patients with small fibroids [8]. Far
field side effects and risks are attributed to bone and nerves
heating due to HI-FU absorbance. During the planning stage
of the procedure, these structures are carefully marked (see
Figure 2) and, for safety reasons, the minimal distance
between the posterior treatment area and bone surface should
be no less than 4 cm [10–12]. Potential risk of deep venous
thrombosis from lying in a supine position for up to 3-4 hours
is substantiallymitigated by the use of compression stockings.
We calculated the NPV with an independent workstation
(Apple iMac 27󸀠󸀠 late 2013) using the region of interest tool of
the Horos software (⟨https://www.horosproject.org/⟩), a free,
open source medical image viewer software based upon
OsiriX and other open source medical imaging libraries
available under the GNU Lesser General Public License,
Version 3 (LGPL-3.0).
AnMRI examination follow-upwas scheduled at 3, 6, and
12months after treatment to evaluate the amount of reduction
in fibroid volume and to assess the presence of residual viable
tissue. The Symptom Severity Score (SSS) was assessed in all
the patients who have signed the additional informed consent
for research purposes at the time of enrolment and on each
MRI follow-up, by the use of the Uterine Fibroids Symptom
and Quality of Life (UFS-QoL) questionnaire [13].
We present a selection of five patients with symptomatic
uterine fibroids treated with MRgFUS at our center. These
cases have distinctive features that offer good points for dis-
cussion.
3. Case 1
A 43-year-old nulliparous female presented with heavy
menstrual bleeding, anemia, pelvic pain, and infertility. The
screening MRI showed multiple fibroids (at least six); the
three largest ranged from 3.5 cm to 5.7 cm (total volume
107.18 cc) and were hypointense on T2-w images (relative to
the uterine wall) and viable on postcontrast T1-w images that
were considered clinically significant for patient symptoms
(SSS = 61).
In this case, the rectum was filled with about 250 cc of US
gel to displace the uterus anteriorly and bowel out of the
treatment path. T2-w images were acquired for treatment
planning. Three ROT were then defined on the targeted
fibroids. Treatment duration was 3 h 55min (calculated from
the first to the last sonication); 102 sonications were per-
formed with an HI-FU energy range of 1600 to 4500 J. The
treatment protocol used included small, large, and elongated
sonication spots depending on the size of the targeted fibroid.
Temperature achieved was in the range of 65–90∘C. Contrast-
enhanced images were acquired at the end of the treatment
and showed a total nonperfused volume (NPV) of 80.45 cc,
achieving an NPV ratio (NPV ratio = nonperfused volume/
perfused volume expressed as percentage) of 75%.
This case illustrates that smaller fibroids located in the
near field and not directly treated may show as nonperfused
fibroids after treatment (white arrows in Figure 3(a)). A pos-
sible hypothesis to explain this finding may lie in damage to
feeding vessels shared between targeted fibroid and nontar-
geted fibroids [14] or, more likely, to a transient vasospasm
of the feeding vessels of nontargeted fibroids, since, in a sub-
sequent MRI follow-up, the untargeted fibroids showed back
a normal vascularization (black arrows in Figure 3(b)). This
finding is not common but should be taken into account
when treating patients with similar conditions as it couldmis-
lead the physician.At 3, 6, and 12months of follow-up, her SSS
score has reduced to 23, 22, and 18 points, respectively, and
the reduction in total tumor size, as a percentage of initial
tumor volume, was 42%, 46%, and 50%, respectively.
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Figure 3: Case 1: (a) sagittal T1-w with fat saturation acquired after intravenous injection of paramagnetic contrast medium showing the
two small fibroids (white arrows) located in the near field that were not directly treated but that became nonperfused too after the treatment;
two bigger fibroids treated are visible too; (b) a follow-upMRI (T1-w with fat saturation acquired after intravenous injection of paramagnetic
contrast medium) showing a normal vascularization of the two small fibroids.
4. Case 2
A 33-year-old female presented with menometrorrhagia and
infertility (SSS = 67). The screening MRI showed multiple
small fibroids, at least 11, of which there was only one treatable
(size: 5 cm; volume: 51.50 cc) intramural fibroid, homoge-
nously hypointense on T2-w images (asterisk in Figure 4),
involving the right side of the fundus of the uterus with an
heterogeneous enhancement on postcontrast T1-w images.
An abdominal scar and some bowel loops were preventing a
direct targeting of the region of treatment, but some expe-
dients have allowed us to effectively treat this patient. The
abdominal scar was covered by an energy-blocking scar patch
to avoid the risk of any skin burns. Bowel obstructing the
beam path was mitigated using a custom sliced 45mm thick
cylindrical gel pad (a circular segment equal to about one-
sixth of the diameter was sliced off from the cranial part; see
dashed line in Figure 4); furthermore, rectum was filled with
about 300 cc of US gel and bladder with about 350 cc of saline.
Bowel loops were able to be displaced superiorly and out of
the beam pathway (curved arrow in Figure 4). The treatment
was performed through the full bladder (B in Figure 4)
demonstrating how even challenging cases can be treated if
the physician succeeds to find a way to expose the ROT. In
this patient, we defined only one ROT, around the biggest
fibroid, because the other smaller fibroids were not accessible
and smaller than 3 cm.
The fibroid was treated in 1 h 40min, using 43 sonications
(energy range: 1100–2250 J; temperature range: 59–102∘C).
The treatment protocol used included large and elongated
spots. Posttreatment, a nonperfused volume of 46 cc and an
NPV ratio of 89% were calculated. At 6 months of follow-up,
her SSS score has reduced to 35 points and the shrinkage of
the treated fibroid was 46% compared to initial fibroid vol-
ume.
∗
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Figure 4: Case 2: sagittal T2-w intraoperative scan showing the
targeted fibroid (asterisk) and full bladder (B) with urinary catheter
present. Bowels obstructing the beam path were mitigated using
a custom sliced (dashed line) gel pad (GP) and rectal filling with
ultrasound gel (R). Curved arrow mimics the dislocation of the
bowel loops.This treatment was successfully performed through the
full bladder.
5. Case 3
A 45-year-old female presented with dysmenorrhea, heavy
bleeding, anemia, and pelvic pain (SSS scored 66 points).
MRI of the pelvis showed two fibroids, both hypointense on
T2-w images; the largest one (diameter 7.3 cm; volume
164.07 cc) was intramural, involving the right side of the fun-
dus of the uterus and the other one was a very small (diam-
eter 2.5 cm; volume 5.73 cc) intracavitary submucosal fibroid
(white arrow in Figure 5(a)). Postgadolinium contrast images
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Figure 5: Case 3: (a) screening coronal T2-w showing the bigger intramural fibroid on the right wall of the uterus, the small intracavitary
submucosal fibroid on the mid left (white arrow), and one more small intramural fibroid on the left wall of the uterus; (b) axial T1-w acquired
after intravenous injection of paramagnetic contrast medium acquired at the end of the treatment showing treated fibroids as nonenhancing
round lesions (white arrow on the small intracavitary submucosal fibroid); (c) in a follow-upMRI, the small intracavitary submucosal fibroid
was no more appreciable; the white arrow shows the “empty” uterine cavity after spontaneous vaginal expulsion.
revealed homogeneous enhancement of both fibroids. Rec-
tumwas filled with 250 cc of US gel bringing the uterus closer
to the anterior abdominal wall.
Treatment duration was 2 h 15min, using 82 sonications
with an energy range of 1700–5100 J. Temperature achieved
was in the range of 60–100∘C.
PosttreatmentMR images revealed a nonperfused volume
of 125.85 cc (NPV ratio of 77%) in the intramural fibroid and a
nonperfused volume of 6.01 cc (NPV ratio > 100%) in the
intracavitary fibroid.
This case shows that small intracavitary fibroids may be
treated safely; ablating an intracavitary fibroid (white arrow
in Figure 5(b)) and its stalks will cause its disconnection
from uterine wall, followed by spontaneous vaginal expulsion
without any complications (see the 3-month follow-up MRI
shown in Figure 5(c)).
At 3, 6, and 12 months of follow-up, her SSS score has
reduced to 26, 23, and 19 points, respectively, and the shrink-
age of the treated intramural fibroid was 40%, 42%, and 49%,
respectively, compared to initial fibroid volume.
6. Cases 4 and 5
Both 38-year-old (case 4) and 44-year-old (case 5) multi-
parous females presented with heavy and prolonged men-
strual flow, pelvic pain, and pressure. Their SSS were 68 and
65, respectively.
The patient in case 4 had a screening MRI demonstrating
a single fibroid (3.6 cm in size with volume of 15.19 cc;
Figure 6(a)), involving the fundus of the uterus; patient in
case 5 showed two fibroids, of which only the larger ante-
rior one (diameter 4 cm; volume 21.45 cc; Figure 7(a)) was
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Figure 6: Case 4: example of a treatment with a low ablation rate (NPV = 57%); (a) screening axial T2-w scan; (b) sagittal T1-w with fat
saturation acquired after intravenous injection of paramagnetic contrast medium acquired at the end of the treatment.
(a) (b)
Figure 7: Case 5: example of a treatment with a very high ablation rate (NPV = 99%); (a) screening axial T2-w scan; (b) sagittal T1-w with
fat saturation acquired after intravenous injection of paramagnetic contrast medium acquired at the end of the treatment.
treatable because the smaller one was posterior and not fully
accessible. In both cases, suitable fibroidswere homogenously
hypointense on T2-w images and showed homogenous en-
hancement on postcontrast T1-w images. Patient in case 4 had
an abdominal transverse scar thatwas covered by a scar patch.
This patient was treated after filling the rectum with 250 cc of
US gel, while patient in case 5was treated with a partially full
bladder to displace bowels superiorly.
Patient in case 4 was treated in 1 h 55min, using 36 son-
ications with an energy range of 1259–2770 J using large and
elongated spots. Temperature achieved was in the range of
39–96∘C. Posttreatment images showed a nonperfused vol-
ume of 8.62 cc and NPV ratio of 57% (Figure 6(b)). At 3, 6,
and 12months of follow-up, therewas a significant decrease in
her SSS score to 21, 19, and 12 points, respectively, and fibroid
size had been reduced from baseline by 27%, 62%, and 81%,
respectively.
Patient in case 5 was treated in 1 h 15min, using 31
sonications with an energy range of 1051–446 J using small,
large, and elongated spots. Temperature achieved was in the
range of 45–97∘C. Posttreatment, a nonperfused volume of
21.30 cc andNPV ratio of 99%were achieved (Figure 7(b)). At
3, 6, and 12months of follow-up, her SSS has reduced to 58, 55,
and 52 points, respectively, and the shrinkage of the treated
fibroid from baseline was 46%, 55%, and 58%, respectively.
Despite similar symptoms and SSSs, patient in case 4
resulted in only a 57%NPV ratiowith a significant decrease in
her SSS (from 68 to 21 at the 3-month follow-up) if compared
to patient in case 5 that resulted in a 99%NPV ratio with only
a slight reduction in her SSS (from 65 to 52 even one year
after the treatment).We presented these two cases together to
highlight how there is not always a clear correlation between
reduction in symptoms and reduction in tumor size even in
patients with similar symptoms and SSS.
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7. Discussion
Several studies have been published focusing on patient
symptomatic relief and fibroid shrinkage.
In our experience, all the treatments were successfully
completed without complications and the patients were
discharged 30min later after the anesthesiologist confirmed
a full recovery from the conscious sedation protocol used.
The following day patients returned to their normal daily
activities and job outside their home when applicable.
Although this is not always true, in our practice, we have
often observed that patients with larger treated volumes have
reported an higher degree of symptom improvement and
required no alternative treatments. This trend has been
already reported in the English literature [15].Thus, it is fair to
always aim at the highest nonperfused volume (at least 60%
for a successful treatment), as there is a close relationship
between the NPV and clinical outcomes [16]. However, our
report suggests that the extent of change in both volume and
symptom score varies largely among the patients and there is
not always a close correlation between the volume of ablated
tissue and the clinical outcome. Nevertheless, there are sev-
eral predictors of success of an MRgFUS treatment, namely,
low signal intensity on T2-weighted images before treatment
and nonperfused tissue volume over at least 20% [7].
MRgFUS for uterine fibroids offers several advantages
over other fibroid therapies including the following: it is an
outpatient procedure, requiring no hospitalization, has a very
low complication rate, utilizes no ionizing radiation, and
allows the patient to return to her normal daily activities the
day after treatment. Furthermore, patients need only con-
scious sedation allowing patients to communicate with the
treating physician and halt treatment if needed.
MRgFUS has a good safety profile. Careful supervision
by the operating physician and detailed preparation of the
patient are important in minimizing uncommon severe
complications as bowel perforation, skin burns, and deep vein
thrombosis. It can be carried out even in anemic patients and
those who are at risk for surgical operation. It represents an
effective and almost noninvasive approach that may be used
as a fertility-preserving technique [4]. A number of reports
of successful treatment have been published [17–19] showing
the feasibility of pregnancy following MRgFUS.
8. Conclusion
We have presented a selection of five cases of adult females
with symptomatic uterine fibroids treated withMRgFUS.The
cases we presented had some distinctive features of interest
ranging from technical measures which enabled establishing
a safe treatment pathway to uncommon posttreatment find-
ings and demonstration of variable clinical response that does
not always correlate with the percentage of tumor ablation
calculated. As for all newly introduced therapeutic pro-
cedures, many points will be clarified only with further
investigations, additional research, and multicenter studies.
MRgFUS represents an effective and almost noninvasive
approach that may be used as a fertility-preserving technique
for the treatment of symptomatic uterine fibroids. It is a
disruptive technology with a remarkable potential in terms of
improved outcomes, safety and efficacy, faster recovery, and
sustained symptomatic relief and, in the near future, it could
cause a sea change in current clinical surgical care. However,
this will really happen only when health regulatory systems
begin to include this procedure among those reimbursable to
extend this treatment option to undeserved patients.
Nowadays, minimally invasive or noninvasive surgical
applications are steadily increasing thanks to the continuous
technological developments that characterize this particular
historical period. Increasingly, imaging-basedmethods today
are used not only for a preliminary assessment or a conven-
tional preoperative planning of many surgical procedures but
also for live monitoring too.
MRgFUS is one of the emerging technologies offering
treating providers image guidance and thermal monitoring.
MRgFUS is a noninvasive safe and effective treatment option
for uterine fibroids [20]. The feasibility and the safety of
MRgFUS have been tested in a growing number of clinical
studies and applications such as painful bonemetastases [21],
musculoskeletal diseases [22], and various other benign and
malignant tumors, like breast cancer [23], bone tumors [24],
prostate [25], liver [26], and pancreatic cancer [26, 27] and,
more recently, it has been used for noninvasive transcranial
applications too [28–32]. MRgFUS is evolving as an alterna-
tive or complementary therapy to current treatment options
such as surgery, radiotherapy, other thermal ablation proce-
dures, gene therapy, and chemotherapy.
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